A Rapid Method for Retrovirus-Mediated Identification of Complementation Groups in Fanconi Anemia Patients

• Published in: Molecular therapy Vol. 12; no. 5; pp. 976 - 984
• Main Authors: Chandra, Saurabh, Levran, Orna, Jurickova, Ingrid, Maas, Chiel, Kapur, Rick, Schindler, Detlev, Henry, Rashida, Milton, Kelly, Batish, Sat Dev, Cancelas, Jose A, Hanenberg, Helmut, Auerbach, Arleen D, Williams, David A
• Format: Journal Article
• Language: English
• Published: United States Elsevier Limited 01.11.2005
• Subjects: Anemia; Cell cycle; Cell Line; Diagnostic tests; DNA Mutational Analysis - methods; Fanconi Anemia - genetics; Fanconi Anemia Complementation Group Proteins - genetics; Flow cytometry; Gene therapy; Gene Transfer Techniques; Genetic Complementation Test; Genetic Vectors; Genotype & phenotype; Green Fluorescent Proteins; Hematology; Humans; Mutation; Proteins; Retroviridae - genetics; Transfection; Vectors (Biology); United States > US; Germany
• ISSN: 1525-0016; 1525-0024
• DOI: 10.1016/j.ymthe.2005.04.021

Fanconi anemia (FA) is a rare autosomal recessive disorder that results from mutations in at least 11 different genes. Recent studies have demonstrated that clinical progression of the disease may be influenced by inter- and intragenic variations, emphasizing the importance of identifying the complementation groups. In the present study we have employed bicistronic retrovirus vectors that coexpress FA-specific cDNAs for complementation groups A, C, F, and G, together with the enhanced green fluorescence protein (EGFP), allowing for specific analysis of transduced EGFP+ cells within bulk cultures by flow cytometry. In addition, the assay relies on the correction of the characteristic FA-associated G2/M arrest after treatment of cells with DNA-damaging agents, which is analyzed by flow cytometry. Results obtained with this assay matched the complementation groups known for 12 control lymphoblast cell lines tested. We report here the results obtained for 48 FA patients with unknown complementation groups using this new assay. Complementation groups were identified for 24 patients. We have identified mutations in the genes corresponding to the assigned complementation group in 23 samples. This assay has now been established in a standardized fashion for complementation assignments in FA patients and the subsequent directing of rapid mutation analysis in those patients.